Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Haploidentical stem cells combined with a small dose of umbilical cord blood transplantation exert similar survival outcome of HLA-matched stem cells transplantation in T-cell acute lymphoblastic leukemia

Bone Marrow Transplantation volume 55, pages 1197–1199 (2020)Cite this article

Subjects

In an effort to increase the applicability of allogeneic hematopoietic stem cell transplantation, alternative donors, such as haploidentical donors and umbilical cord blood (UCB) stem cell products are frequently used when a well matched donor is unavailable, but each of which has its own inherent advantages and disadvantages [1, 2]. UCB stem cell transplantation (SCT) causes little graft-versus-host disease(GVHD) [3], but may lead to delayed and unpredictable hematopoietic recovery [4]. Haploidentical SCT increases the incidence of acute GVHD, nonrelapse mortality, but the rapid engraftment is its advantage [5, 6]. In order to bypass their drawbacks and retain the graft versus leukemia of the haploidentical donor, we recently attempted a transplantation strategy of myeloablative haplo-SCT combined with unrelated cord blood as a third-party donor support (haplo-cord SCT), and found that the co-infusion of an unrelated cord blood unit may potentially improve the outcome of haploidentical allogeneic hematopoietic SCT in MDS, AML, and B-ALL [7, 8]. However, data on a large number of T-ALL studies are lacking to evaluated the haplo-cord SCT in T-ALL. Hence, we assessed the strategy of haplo-cord SCT and compared it with HLA-matched donor SCT (MD-SCT) for treatment of T-ALL patients by a retrospective study based on the transplantation database in the First Affiliated Hospital of Soochow University.

A cohort of 129 patients with T-ALL, who underwent allo-SCT between December 2005 and June 2018, were included in this study. Among them, 72 patients received haplo-cord SCT, who did not have HLA-matched donors; 57 patients received MD-SCT of 29 related donors and 28 unrelated donors. This study was performed in accordance to the Declaration of Helsinki. Written informed consent for submitting data to our database was routinely obtained when a patient was admitted to our center, which was approved by our hospital’s Ethics Committee.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Ballen KK, Spitzer TR. The great debate: haploidentical or cord blood transplant. Bone Marrow Transpl. 2011;46:323–9.

    Article  CAS  Google Scholar 

  2. Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transpl. 2015;50:1037–56.

    Article  CAS  Google Scholar 

  3. Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. 2007;109:1322–30.

    Article  CAS  Google Scholar 

  4. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010;116:4693–9.

    Article  CAS  Google Scholar 

  5. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125:3956–62.

    Article  CAS  Google Scholar 

  6. Wang Y, Wang HX, Lai YR, Sun ZM, Wu DP, Jiang M, et al. Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia. 2016;30:2055–63.

    Article  CAS  Google Scholar 

  7. Chen J, Wang RX, Chen F, Sun AN, Qiu HY, Jin ZM, et al. Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study. Bone Marrow Transpl. 2014;49:206–11.

    Article  CAS  Google Scholar 

  8. Ke P, Bao XB, Hu XH, Zhuang J, Wu XJ, Liu YJ, et al. Myeloablative conditioning regimens with combined of haploidentical and cord blood transplantation for myelodysplastic syndrome patients. Bone Marrow Transpl. 2018;53:162–8.

    Article  CAS  Google Scholar 

  9. Kwon M, Bautista G, Balsalobre P, Sanchez-Ortega I, Serrano D, Anguita J, et al. Haplo-cord transplantation using CD34+ cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders. Biol Blood Marrow Transpl. 2014;20:2015–22.

    Article  CAS  Google Scholar 

  10. Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011;118:6438–45.

    Article  CAS  Google Scholar 

  11. Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100:1611–8.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 81470346, 81773361), Jiangsu Natural Science Foundation (BK20161204), Jiangsu Social Development Projects (BE2018651), Jiangsu “333” Talent Project (BRA2015497), the National Key Research and Development Program (2016YFC0902800), Innovation Capability Development Project of Jiangsu Province (BM2015004), Jiangsu Summit Six Top Talent Person Project and Jiangsu Medical Junior Talent Person Award (QNRC2016707), Xuzhou Science and Technology Plan Project (KC18022).

Author information

Author notes

  1. These authors contributed equally: Jinge Xu, Ranran Zhao, Lulu Yang

Authors and Affiliations

  1. The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China

    Jinge Xu, Ranran Zhao, Lulu Yang, Huanle Gong, Jia Chen, Hong Liu, Hongjie Shen, Mingqing Zhu, Suning Chen, Xiao Ma, Xiaojin Wu & Depei Wu

  2. Institute of Blood and Marrow Transplantation, Suzhou, China

    Jinge Xu, Ranran Zhao, Lulu Yang, Huanle Gong, Shoubao Ma, Jia Chen, Hong Liu, Hongjie Shen, Mingqing Zhu, Suning Chen, Xiao Ma, Xiaojin Wu & Depei Wu

  3. The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China

    Jinge Xu

Authors
  1. Jinge Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ranran Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lulu Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huanle Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shoubao Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jia Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hongjie Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mingqing Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Suning Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Xiao Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Xiaojin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Depei Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xiaojin Wu or Depei Wu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, J., Zhao, R., Yang, L. et al. Haploidentical stem cells combined with a small dose of umbilical cord blood transplantation exert similar survival outcome of HLA-matched stem cells transplantation in T-cell acute lymphoblastic leukemia. Bone Marrow Transplant 55, 1197–1199 (2020). https://doi.org/10.1038/s41409-019-0666-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0666-2

Search

Advanced search

Quick links